Medicare proposes covering weight-loss drugs, teeing up clash with RFK Jr. - The Boston Globe
- Bias Rating
10% Center
- Reliability
35% ReliableFair
- Policy Leaning
10% Center
- Politician Portrayal
-17% Negative
Continue For Free
Create your free account to see the in-depth bias analytics and more.
Continue
Continue
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates. Already a member: Log inBias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
8% Positive
- Liberal
- Conservative
Sentence | Sentiment | Bias |
---|---|---|
Unlock this feature by upgrading to the Pro plan. |
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
59% : The Biden administration's proposal was crafted by the Centers for Medicare and Medicaid Services and is scheduled to be issued at 8:45 a.m. in the Federal Register.48% : While the rules were written for the Medicare program, which covers older Americans, the new interpretation of weight-loss drugs also applies to Medicaid, which covers low-income Americans.
47% : Becerra said the proposal would expand coverage of antiobesity drugs to 7.5 million people enrolled in Medicare and Medicaid, which his agency projected would add $25 billion in Medicare costs and $11 billion in Medicaid costs during the next decade.
46% : Under current rules, Medicare does not cover weight-loss medication, although many beneficiaries receive drugs such as Ozempic and Wegovy to treat diabetes and heart disease, conditions that can be exacerbated by obesity.
46% : The Congressional Budget Office, a nonpartisan agency, last month concluded that expanding coverage to antiobesity drugs would cost Medicare an additional $35 billion between 2026 and 2034 - a figure higher than what the Biden administration estimates.
45% : Becerra said the additional costs represented a modest fraction of the forecasted spending for Medicare, citing estimates that the program is expected to spend more than $2 trillion on drugs across the next decade.
44% : Six in 10 adults believe that Medicare should cover the drugs for weight loss, with Democrats somewhat more likely than Republicans to be in favor, according to a poll released in May by KFF, a nonpartisan health-care research organization.
41% : Biden officials seeking to finalize their weight-loss proposal may find an ally in Mehmet Oz, the TV personality and cardiothoracic surgeon whom Trump last week tapped to lead CMS.
34% : Robert F. Kennedy Jr. - whom Trump has selected to be the next HHS secretary, if confirmed by the Senate - is an avowed critic of weight-loss drugs such as Ozempic, which he has blamed for obfuscating the root causes of poor health in America.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.